LD-2 disclosure · 2nd Quarter - Report
ATEA PHARMACEUTICALS
Coverage · No income or expenses were reported on this filing.
Client
- Description
- Drug development and COVID 19 issues involving FDA, DOD, HHS, and OWS
- Location
- Massachusetts · United States of America
Registrant
- Description
- Government Affairs Strategies and Advice
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueHealth Issues
Issues specifically related to Covid drug development.
LobbyistsBURT ROSEN
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)